A randomised trial of the EURopean and AMerican Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy

Submission date	Recruitment status	Prospectively registered
24/08/2004	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	[X] Results
Last Edited	Condition category	[] Individual participant data
19/10/2018	Cancer	

Plain English summary of protocol

http://www.cancerhelp.org.uk/trials/a-trial-looking-at-treatment-after-surgery-for-people-with-osteosarcoma

Study website

http://www.ctu.mrc.ac.uk/euramos/euramos_i_trial.asp

Contact information

Type(s)

Scientific

Contact name

Dr Jeremy Whelan

Contact details

The Middlesex Hospital UCL Hospitals NHS Trust Mortimer Street London United Kingdom W1T 3AA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

NCT00134030

Secondary identifying numbers

N/A

Study information

Scientific Title

A randomised trial of the EURopean and AMerican Osteosarcoma Study group to optimize treatment strategies for resectable osteosarcoma based on histological response to preoperative chemotherapy

Acronym

EURAMOS 1

Study objectives

Study hypothesis added as of 10/09/2008:

Primary objectives:

- 1. To examine, in a randomised controlled trial, whether the addition of ifosfamide and etoposide (IE) to post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a poor histological response to 10 weeks of pre-operative chemotherapy.
- 2. To examine, in a randomised controlled trial, whether the addition of interferon-alpha ifn) as maintenance therapy after post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a good histological response to 10 weeks of pre-operative chemotherapy.

Secondary objectives:

- 3. To investigate whether the addition of IE to post-operative therapy for poor responders, and the addition of ifn as maintenance therapy for good responders, leads to an improvement in overall survival, short-term toxicity, long-term toxicity and quality of life.
- 4. To investigate whether the addition of IE to post-operative therapy for poor responders, and the addition of ifn as maintenance therapy for good responders, leads to an improvement in event-free and overall survival in patients with localized osteosarcoma at entry.
- 5. To investigate whether biological or clinical correlates to histological response and outcome can be identified.
- 6. To establish whether this international cooperation in clinical trials for osteosarcoma is feasible.

Please note that the target number of participants has been added as of 10/09/2008.

On 08/02/2011 the overall trial end date was changed from 30/03/2009 to 30/06/2011.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Trent Multi-centre Research Ethics Committee, 07/01/2005, ref: 04/MRE04/79

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Osteosarcoma

Interventions

All patients who are registered on this study will receive pre-operative chemotherapy with MAP for about 10 weeks. Following surgery for the primary tumour, the histological response to pre-operative chemotherapy will be assessed. Good responders (<10% viable tumor) will be randomized to receive either MAP or MAPIFn. Poor responders (≥10% viable tumor) will be randomized to receive either MAP or MAPIE.

MAP = methotrexate, doxorubicin and cisplatin

MAPifn = methotrexate, doxorubicin and cisplatin followed by pegylated interferon alpha MAPIE = methotrexate, doxorubicin, cisplatin, ifosfamide and etoposide

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Methotrexate, doxorubicin, cisplatin, pegylated interferon alpha, ifosfamide, etoposide

Primary outcome measure

Added as of 10/09/2008:

Event-free survival

Secondary outcome measures

Added as of 10/09/2008:

- 1. Overall survival
- 2. Toxicity as measured by CTCAE v3.0
- 3. Quality of life

Overall study start date

30/03/2004

Completion date

30/06/2011

Eligibility

Key inclusion criteria

Eligible patients will be registered, then following assessment of histological response of primary tumor, may be eligible for randomisation.

Patients must fulfill the following criteria for registration into the trial:

- 1. Histological evidence of high grade osteosarcoma of the extremity or axial skeleton including those arising as second malignancies
- 2. Resectable disease
- 3. Aged 40 years or less at date of diagnostic biopsy
- 4. Registration within 30 days of diagnostic biopsy
- 5. Start chemotherapy within 30 days of diagnostic biopsy
- 6. Neutrophils more than or equal to 1.5 x 10^9/L (or white blood cell count [WBC] more than or equal to 3 x 10^9/L if neutrophils are not available) and platelet count more than or equal to 100 x 10^9 /L
- 7. Glomerular Filtration Rate more than or equal to 70 ml/min/1.73 m^2
- 8. Serum bilirubin more than or equal to 1.5 x Upper Limit of Normal [ULN]
- 9. Sufficient cardiac function to receive anthracyclines: shortening fraction (SF) more than or equal to 28% or ejection fraction (EF) more than or equal to 50%
- 10. Adequate performance status (Karnofsky score more than or equal to 60 or World Health Organisation [WHO] less than or equal to two for patients [aged 16 or over], Lansky score more than or equal to 60 [aged under 16]). Patients whose performance status is adversely affected by a pathologic fracture but who are able to undergo treatment are eligible.
- 11. Patient fit to undergo protocol treatment and follow-up
- 12. Written informed consent

Participant type(s)

Patient

Age group

Mixed

Sex

Both

Target number of participants

1,400

Key exclusion criteria

- 1. Unresectable disease, primary or metastatic or both
- 2. Low grade osteosarcoma
- 3. Juxtacortical (periosteal, parosteal) osteosarcoma
- 4. Craniofacial osteosarcoma
- 5. Any previous treatment for osteosarcoma
- 6. Any previous chemotherapy for any disease
- 7. Any other medical condition precluding treatment with protocol chemotherapy (for example Human Immunodeficiency Virus [HIV], psychiatric disorder etc.)
- 8. Pregnant or lactating women

Patients must fulfill the following criteria for randomisation into the trial:

- 1. Assessment of histological response in primary tumor within 35 days of definitive surgery
- 2. Exactly two courses of cisplatin and doxorubicin must have been administered before surgery
- 3. At least two courses and no more than six courses of methotrexate must have been administered before surgery
- 4. Recovery from prior therapy allowing administration of chemotherapy
- 5. No progression of metastatic disease or new metastatic disease
- 6. Macroscopically complete surgical resection of the primary tumor
- 7. In patients with metastatic disease, complete removal of all metastases or complete removal planned and deemed feasible
- 8. Age more than or equal to five for patients with good response
- 9. Essential data collection will be provided
- 10. Written consent to undergo randomisation

D	a	te	of	fir	st	en	ГО	lm	e	٦t

30/03/2004

Date of final enrolment

30/06/2011

Locations

Countries o	f recru	itmen	t
-------------	---------	-------	---

Austria

Belgium

Canada

Czech Republic

England

Finland

Ireland

New Zealand

Puerto Rico

Switzerland

United Kingdom

United States of America

Study participating centre The Middlesex Hospital London United Kingdom W1T 3AA

Sponsor information

Organisation

Medical Research Council (UK)

Sponsor details

c/o lan Viney MRC Centre London Stehenson House 158-160 North Gower Street London United Kingdom NW1 2DA

Sponsor type

Government

Website

http://www.mrc.ac.uk

ROR

https://ror.org/03x94j517

Funder(s)

Funder type

Research organisation

Funder Name

European Science Foundation (ESF)

Alternative Name(s)

ESF

Funding Body Type

Private sector organisation

Funding Body Subtype

International organizations

Location

France

Funder Name

Clinical Trials Awards and Advisory Committee (UK)

Funder Name

Deutsche Krebshilfe (Germany)

Funder Name

Swedish Cancer Society and Nordic Cancer Union (Scandinavian countries)

Funder Name

Childrens Oncology Group (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output typeDetailsDate createdDate addedPeer reviewed?Patient-facing?Plain English resultsNoYes

Results article	results	01/02/2015	Yes	No
Results article	results	10/07/2015	Yes	No